“Alzheimer’s meds are here. But for the Down syndrome community, it’s still the 1980s”
by Annalee Armstrong, Fierce Biotech
An important article from industry publication Fierce Biotech highlights the lack of inclusion of the Down syndrome community in Alzheimer’s research. LuMind IDSC Chief Scientific Officer Richard Fisher explained the barriers that still need to be addressed before people with Down syndrome will have access to the latest class of Alzheimer’s therapies. Read the full article here.
We hope researchers and policymakers will hear this call to action!
